Excerpt from our Wall Street Breakfast, a one-page summary of this morning's key market-moving and stock-moving stories:
Summary: Shares of Dynavax Technologies Corp. increased by nearly 33% yesterday after the drug developer released positive late-stage trial data for its hepatitis B vaccine, Heplisav. The late phase trial was proven to successfully protect the "difficult-to-immunize" over-40 population, which includes patients on kidney dialysis. Dynavax claimed the data showed its vaccine was superior to conventional hepatitis B vaccines; its two main competitors would be Engerix-B from GlaxoSmithKline and Recombivax from Merck & Co.
Related links: Commentary: Dynavax Shares Jump on Positive Hepatitis Study • New England Journal of Medicine on other DVAX products • Street Insider [sub. req.].
Potentially impacted stocks and ETFs: Dynavax Technologies Corp. (DVIX), GlaxoSmithKline (NYSE:GSK), Merck & Co. (NYSE:MRK) • ETFs: PowerShares Dynamic Biotech & Genome (NYSEARCA:PBE).
Seeking Alpha is not affiliated with AP.